Your browser doesn't support javascript.
loading
Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Kantarjian, Hagop M; Hughes, Timothy P; Larson, Richard A; Kim, Dong-Wook; Issaragrisil, Surapol; le Coutre, Philipp; Etienne, Gabriel; Boquimpani, Carla; Pasquini, Ricardo; Clark, Richard E; Dubruille, Viviane; Flinn, Ian W; Kyrcz-Krzemien, Slawomira; Medras, Ewa; Zanichelli, Maria; Bendit, Israel; Cacciatore, Silvia; Titorenko, Ksenia; Aimone, Paola; Saglio, Giuseppe; Hochhaus, Andreas.
Afiliación
  • Kantarjian HM; The University of Texas MD Anderson Cancer Center, Houston, TX, USA. hkantarjian@mdanderson.org.
  • Hughes TP; South Australian Health and Medical Research Institute, Adelaide, SA, Australia.
  • Larson RA; University of Adelaide, Adelaide, SA, Australia.
  • Kim DW; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
  • Issaragrisil S; Seoul St. Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul, South Korea.
  • le Coutre P; Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Etienne G; Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Boquimpani C; Hematology Department, Institut Bergonié, Bordeaux, France.
  • Pasquini R; Hemorio, Institute of Hematology, Rio de Janeiro, Brazil.
  • Clark RE; Oncoclínica Rio de Janeiro, Rio de Janeiro, Brazil.
  • Dubruille V; Universidade Federal do Paraná, Hospital de Clinicas, Curitiba, Paraná, Brazil.
  • Flinn IW; Royal Liverpool University Hospital, Liverpool, United Kingdom.
  • Kyrcz-Krzemien S; Clinical Hematology, Nantes University Hospital, Nantes, France.
  • Medras E; Sarah Cannon Research Institute, Nashville, TN, USA.
  • Zanichelli M; Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland.
  • Bendit I; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
  • Cacciatore S; Instituto de Tratamento do Câncer Infantil, Instituto da Criança, Hospital das Clínicas, Universidade de São Paulo, São Paulo, Brazil.
  • Titorenko K; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
  • Aimone P; Novartis Pharma AG, Basel, Switzerland.
  • Saglio G; Novartis Pharmaceuticals Corporation, Moscow, Russian Federation.
  • Hochhaus A; Novartis Pharma AG, Basel, Switzerland.
Leukemia ; 35(7): 2142-2143, 2021 Jul.
Article en En | MEDLINE | ID: mdl-34108614
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido